ABC transporters, bile acids, and inflammatory stress in liver cancer

Current Pharmaceutical Biotechnology

Volumn 12, Issue 4, 2011, Pages 636-646

  Wang, Renxue ^a   Sheps, Jonathan A ^a   Ling, Victor ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Bile acid; Bile formation; Bile salt export pump (BSEP); Cancer; Inflammation; Liver; Multi drug resistance protein 1 (MDR1)

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G5; ABC TRANSPORTER G8; BILE ACID; CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; BILE SECRETION; DRUG TARGETING; HUMAN; INFLAMMATION; LIVER CANCER; LIVER CELL; LIVER INJURY; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; HEPATITIS; HUMANS; LIVER; LIVER NEOPLASMS; OXIDATIVE STRESS;

MUS;

EID: 79953791507     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795163986     Document Type: Article

References (129)

1. Aggarwal, B. B.; Gehlot, P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr. Opin. Pharmacol., 2009, 9 (4), 351-369.
2. Grivennikov, S. I.; Karin, M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev., 2010, 20 (1), 65-71.
3. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454 (7203), 436-444.
4. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 2001, 11 (7), 1156-1166.
5. Knisely, A. S.; Strautnieks, S. S.; Meier, Y.; Stieger, B.; Byrne, J. A.; Portmann, B. C.; Bull, L. N.; Pawlikowska, L.; Bilezikci, B.; Ozcay, F.; Laszlo, A.; Tiszlavicz, L.; Moore, L.; Raftos, J.; Arnell, H.; Fischler, B.; Nemeth, A.; Papadogiannakis, N.; Cielecka-Kuszyk, J.; Jankowska, I.; Pawlowska, J.; Melin-Aldana, H.; Emerick, K. M.; Whitington, P. F.; Mieli-Vergani, G.; Thompson, R. J. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology, 2006, 44 (2), 478-486.
6. Scheimann, A. O.; Strautnieks, S. S.; Knisely, A. S.; Byrne, J. A.; Thompson, R. J.; Finegold, M. J. Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. J. Pediatr., 2007, 150 (5), 556-559.
7. Smit, J. J.; Schinkel, A. H.; Mol, C. A.; Majoor, D.; Mooi, W. J.; Jongsma, A. P.; Lincke, C. R.; Borst, P. Tissue distribution of the human MDR3 P-glycoprotein. Lab. Invest., 1994, 71 (5), 638-649.
8. Smit, J. J.; Schinkel, A. H.; Oude Elferink, R. P.; Groen, A. K.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Ottenhoff, R.; van der Lugt, N. M.; van Roon, M. A. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 1993, 75 (3), 451-462.
9. Erlinger, S. Cystic fibrosis: bile secretion. Br. Med. Bull., 1992, 48 (4), 860-876.
10. Boyer, J. L.; Sperber I. Secretion of organic anions in the formation of urine and bile [Pharmacol. Rev. 1959;11:109-134]. J. Hepatol., 2002, 36 (1), 4-7.
11. Hofmann, A. F. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med., 1999, 159 (22), 2647-2658.
12. Hofmann, A. F. Bile secretion in mice and men. Hepatology, 2001, 34 (4 Pt 1), 848-850.
13. Wang, R.; Lam, P.; Liu, L.; Forrest, D.; Yousef, I. M.; Mignault, D.; Phillips, M. J.; Ling, V. Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatology, 2003, 38 (6), 1489-1499.
14. Wang, R.; Salem, M.; Yousef, I. M.; Tuchweber, B.; Lam, P.; Childs, S. J.; Helgason, C. D.; Ackerley, C.; Phillips, M. J.; Ling, V. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA, 2001, 98 (4), 2011-2016.
15. Paulusma, C. C.; Bosma, P. J.; Zaman, G. J.; Bakker, C. T.; Otter, M.; Scheffer, G. L.; Scheper, R. J.; Borst, P.; Oude Elferink, R. P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science, 1996, 271 (5252), 1126-1128.
16. Hofmann, A. F. Defective biliary secretion during total parenteral nutrition: probable mechanisms and possible solutions. J. Pediatr. Gastroenterol. Nutr., 1995, 20 (4), 376-390.
17. Jansen, P. L.; Sturm, E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int., 2003, 23 (5), 315-322.
18. Muller, M.; Jansen, P. L. Molecular aspects of hepatobiliary transport. Am. J. Physiol., 1997, 272 (6 Pt 1), G1285-1303.
19. Strautnieks, S. S.; Kagalwalla, A. F.; Tanner, M. S.; Knisely, A. S.; Bull, L.; Freimer, N.; Kocoshis, S. A.; Gardiner, R. M.; Thompson, R. J. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am. J. Hum. Genet., 1997, 61 (3), 630-633.
20. Glasova, H.; Beuers, U. Extrahepatic manifestations of cholestasis. J. Gastroenterol. Hepatol., 2002, 17 (9), 938-948.
21. Maddrey, W. C. Bone disease in patients with primary biliary cirrhosis. Prog. Liver Dis., 1990, 9, 537-554.
22. Hofmann, A. F. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev., 2004, 36 (3-4), 703-722.
23. Whitington, P. F. Chronic cholestasis of infancy. Pediatr. Clin. N. Am., 1996, 43 (1), 1-26.
24. Beuers, U. Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3 (6), 318-328.
25. Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov., 2008, 7 (8), 678-693.
26. Chiang, J. Y. Bile acids: regulation of synthesis. J. Lipid. Res., 2009, 50(10), 1955-1966.
27. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 2002, 298 (5), 714-719.
28. Maruyama, T.; Tanaka, K.; Suzuki, J.; Miyoshi, H.; Harada, N.; Nakamura, T.; Miyamoto, Y.; Kanatani, A.; Tamai, Y. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/MBar) in mice. J. Endocrinol., 2006, 191 (1), 197-205.
29. Fickert, P.; Wagner, M.; Marschall, H. U.; Fuchsbichler, A.; Zollner, G.; Tsybrovskyy, O.; Zatloukal, K.; Liu, J.; Waalkes, M. P.; Cover, C.; Denk, H.; Hofmann, A. F.; Jaeschke, H.; Trauner, M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 2006, 130 (2), 465-481.
30. Trauner, M.; Fickert, P.; Halilbasic, E.; Moustafa, T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med. Wochenschr., 2008, 158 (19-20), 542-548.
31. Halilbasic, E.; Fiorotto, R.; Fickert, P.; Marschall, H. U.; Moustafa, T.; Spirli, C.; Fuchsbichler, A.; Gumhold, J.; Silbert, D.; Zatloukal, K.; Langner, C.; Maitra, U.; Denk, H.; Hofmann, A. F.; Strazzabosco, M.; Trauner, M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/-mice. Hepatology, 2009, 49 (6), 1972-1981.
32. Shah, S. P.; Morin, R. D.; Khattra, J.; Prentice, L.; Pugh, T.; Burleigh, A.; Delaney, A.; Gelmon, K.; Guliany, R.; Senz, J.; Steidl, C.; Holt, R. A.; Jones, S.; Sun, M.; Leung, G.; Moore, R.; Severson, T.; Taylor, G. A.; Teschendorff, A. E.; Tse, K.; Turashvili, G.; Varhol, R.; Warren, R. L.; Watson, P.; Zhao, Y.; Caldas, C.; Huntsman, D.; Hirst, M.; Marra, M. A.; Aparicio, S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 2009, 461 (7265), 809-813.
33. Gerloff, T.; Meier, P. J.; Stieger, B. Taurocholate induces preferential release of phosphatidylcholine from rat liver canalicular vesicles. Liver, 1998, 18 (5), 306-312.
34. Ruetz, S.; Gros, P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. J. Biol. Chem., 1995, 270 (43), 25388-25395.
35. Schinkel, A. H.; Mol, C. A.; Wagenaar, E.; van Deemter, L.; Smit, J. J.; Borst, P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer, 1995, 31A (7-8), 1295-1298.
36. Smit, J. W.; Schinkel, A. H.; Muller, M.; Weert, B.; Meijer, D. K. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology, 1998, 27 (4), 1056-1063.
37. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 1998, 95 (26), 15665-15670.
38. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C.; Schinkel, A. H.; van De Vijver, M. J.; Scheper, R. J.; Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61 (8), 3458-3464.
39. Merino, G.; Jonker, J. W.; Wagenaar, E.; van Herwaarden, A. E.; Schinkel, A. H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol., 2005, 67 (5), 1758-1764.
40. Berge, K. E.; Tian, H.; Graf, G. A.; Yu, L.; Grishin, N. V.; Schultz, J.; Kwiterovich, P.; Shan, B.; Barnes, R.; Hobbs, H. H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 2000, 290 (5497), 1771-1775.
41. Yu, L.; York, J.; Bergmann Kv, K.; Lutjohann, D.; Cohen, J. C.; Hobbs, H. H. Stimulation of cholesterol excretion by LXR agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem., 2003, 22, 22.
42. Cole, S. P.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54 (22), 5902-5910.
43. Kool, M.; van der Linden, M.; de Haas, M.; Baas, F.; Borst, P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res., 1999, 59 (1), 175-182.
44. Kool, M.; de Haas, M.; Scheffer, G. L.; Scheper, R. J.; van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res., 1997, 57 (16), 3537-3547.
45. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92 (16), 1295-1302.
46. Haimeur, A.; Conseil, G.; Deeley, R. G.; Cole, S. P. The MRPrelated and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab., 2004, 5 (1), 21-53.
47. Kruh, G. D.; Zeng, H.; Rea, P. A.; Liu, G.; Chen, Z. S.; Lee, K.; Belinsky, M. G. MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr., 2001, 33 (6), 493-501.
48. Assem, M.; Schuetz, E. G.; Leggas, M.; Sun, D.; Yasuda, K.; Reid, G.; Zelcer, N.; Adachi, M.; Strom, S.; Evans, R. M.; Moore, D. D.; Borst, P.; Schuetz, J. D. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem., 2004, 279 (21), 22250-22257.
49. Schuetz, E. G.; Strom, S.; Yasuda, K.; Lecureur, V.; Assem, M.; Brimer, C.; Lamba, J.; Kim, R. B.; Ramachandran, V.; Komoroski, B. J.; Venkataramanan, R.; Cai, H.; Sinal, C. J.; Gonzalez, F. J.; Schuetz, J. D. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem., 2001, 276 (42), 39411-39418.
50. Scholmerich, J.; Becher, M. S.; Schmidt, K.; Schubert, R.; Kremer, B.; Feldhaus, S.; Gerok, W. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles. Hepatology, 1984, 4 (4), 661-666.
51. Quist, R. G.; Ton-Nu, H. T.; Lillienau, J.; Hofmann, A. F.; Barrett, K. E. Activation of mast cells by bile acids. Gastroenterology, 1991, 101 (2), 446-456.
52. Heuman, D. M.; Mills, A. S.; McCall, J.; Hylemon, P. B.; Pandak, W. M.; Vlahcevic, Z. R. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology, 1991, 100 (1), 203-211.
53. Shekels, L. L.; Beste, J. E.; Ho, S. B. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J. Lab. Clin. Med., 1996, 127 (1), 57-66.
54. Tan, K. P.; Yang, M.; Ito, S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol. Pharmacol., 2007, 72 (5), 1380-1390.
55. Strautnieks, S. S.; Bull, L. N.; Knisely, A. S.; Kocoshis, S. A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M. S.; Kagalwalla, A. F.; Nemeth, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N. B.; Gardiner, R. M.; Thompson, R. J. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet., 1998, 20 (3), 233-238.
56. Kubitz, R.; Keitel, V.; Scheuring, S.; Kohrer, K.; Haussinger, D. Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. J. Clin. Gastroenterol., 2006, 40 (2), 171-175.
57. Dixon, P. H.; Weerasekera, N.; Linton, K. J.; Donaldson, O.; Chambers, J.; Egginton, E.; Weaver, J.; Nelson-Piercy, C.; de Swiet, M.; Warnes, G.; Elias, E.; Higgins, C. F.; Johnston, D. G.; McCarthy, M. I.; Williamson, C. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet., 2000, 9 (8), 1209-1217.
58. Chen, H. L.; Chang, P. S.; Hsu, H. C.; Lee, J. H.; Ni, Y. H.; Hsu, H. Y.; Jeng, Y. M.; Chang, M. H. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr. Res., 2001, 50 (1), 50-55.
59. Oude Elferink, R. P.; Paulusma, C. C.; Groen, A. K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology, 2006, 130 (3), 908-925.
60. Trauner, M.; Fickert, P.; Wagner, M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis., 2007, 27 (1), 77-98.
61. Mauad, T. H.; van Nieuwkerk, C. M.; Dingemans, K. P.; Smit, J. J.; Schinkel, A. H.; Notenboom, R. G.; van den Bergh Weerman, M. A.; Verkruisen, R. P.; Groen, A. K.; Oude Elferink, R. P. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol., 1994, 145 (5), 1237-1245.
62. Calvisi, D. F.; Factor, V. M.; Ladu, S.; Conner, E. A.; Thorgeirsson, S. S. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology, 2004, 126 (5), 1374-1386.
63. Katzenellenbogen, M.; Mizrahi, L.; Pappo, O.; Klopstock, N.; Olam, D.; Barash, H.; Domany, E.; Galun, E.; Goldenberg, D. Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice. Mol. Cancer Ther., 2007, 6 (4), 1283-1291.
64. Katzenellenbogen, M.; Mizrahi, L.; Pappo, O.; Klopstock, N.; Olam, D.; Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.; Domany, E.; Galun, E.; Goldenberg, D. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res., 2007, 5 (11), 1159-1170.
65. Hubacek, J. A.; Berge, K. E.; Cohen, J. C.; Hobbs, H. H. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum. Mutat., 2001, 18 (4), 359-360.
66. Lu, K.; Lee, M. H.; Hazard, S.; Brooks-Wilson, A.; Hidaka, H.; Kojima, H.; Ose, L.; Stalenhoef, A. F.; Mietinnen, T.; Bjorkhem, I.; Bruckert, E.; Pandya, A.; Brewer, H. B. Jr.; Salen, G.; Dean, M.; Srivastava, A.; Patel, S. B. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet., 2001, 69 (2), 278-290.
67. McGill, J. M.; Williams, D. M.; Hunt, C. M. Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig. Dis. Sci., 1996, 41 (3), 540-542.
68. Feranchak, A. P.; Sokol, R. J. Cholangiocyte biology and cystic fibrosis liver disease. Semin. Liver Dis., 2001, 21 (4), 471-488.
69. Demeilliers, C.; Jacquemin, E.; Barbu, V.; Mergey, M.; Paye, F.; Fouassier, L.; Chignard, N.; Housset, C.; Lomri, N. E. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology, 2006, 43 (5), 1125-1134.
70. Pytrus, T.; Iwanczak, B.; Smigiel, R.; Ryzko, J.; Socha, P.; Iwanczak, F. [Ascites and extreme lipid abnormalities as initial symptoms of cystic fibrosis in a 5-years-old girl--case report]. Pol. Merkur Lekarski, 2009, 27 (161), 388-392.
71. Paulusma, C. C.; Kool, M.; Bosma, P. J.; Scheffer, G. L.; ter Borg, F.; Scheper, R. J.; Tytgat, G. N.; Borst, P.; Baas, F.; Oude Elferink, R. P. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology, 1997, 25 (6), 1539-1542.
72. Jacquemin, E. Progressive familial intrahepatic cholestasis. J. Gastroenterol. Hepatol., 1999, 14 (6), 594-599.
73. Lam, P.; Wang, R.; Ling, V. Bile acid transport in sister of Pglycoprotein (ABCB11) knockout mice. Biochemistry, 2005, 44 (37), 12598-12605.
74. Wang, R.; Chen, H.-L.; Liu, L.; Sheps, J. A.; Phillips, M. J.; Ling, V. Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology, 2009, 50 (3), 948-956.
75. Ferrero-Miliani, L.; Nielsen, O. H.; Andersen, P. S.; Girardin, S. E. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol., 2007, 147 (2), 227-235.
76. Markiewski, M. M.; DeAngelis, R. A.; Lambris, J. D. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol. Immunol., 2006, 43 (1-2), 45-56.
77. Fickert, P.; Fuchsbichler, A.; Wagner, M.; Zollner, G.; Kaser, A.; Tilg, H.; Krause, R.; Lammert, F.; Langner, C.; Zatloukal, K.; Marschall, H. U.; Denk, H.; Trauner, M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 2004, 127 (1), 261-274.
78. Roda, A.; Grigolo, B.; Pellicciari, R.; Natalini, B. Structure-activity relationship studies on natural and synthetic bile acid analogs. Digest. Dis. Sci., 1989, 34 (0), S24-S35.
79. Heuman, D. M.; Pandak, W. M.; Hylemon, P. B.; Vlahcevic, Z. R. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology, 1991, 14 (5), 920-926.
80. Milkiewicz, P.; Roma, M. G.; Elias, E.; Coleman, R. Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways. Gut, 2002, 51 (1), 113-119.
81. Lamireau, T.; Zoltowska, M.; Levy, E.; Yousef, I.; Rosenbaum, J.; Tuchweber, B.; Desmouliere, A. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci., 2003, 72 (12), 1401-1411.
82. Reinehr, R.; Haussinger, D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology, 2004, 126 (1), 249-262.
83. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klaassen, C. D.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA, 2001, 98 (6), 3369-3374.
84. Cohen, B. I.; Hofmann, A. F.; Mosbach, E. H.; Stenger, R. J.; Rothschild, M. A.; Hagey, L. R.; Yoon, Y. B. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology, 1986, 91 (1), 189-197.
85. Zhao, X. M.; Montet, A. M.; Montet, J. C. [beta] muricholic acid: a new hepatoprotective agent. J. Nutr. Biochem., 1993, 4 (2), 105-112.
86. van Nieuwkerk, C. M.; Elferink, R. P.; Groen, A. K.; Ottenhoff, R.; Tytgat, G. N.; Dingemans, K. P.; Van Den Bergh Weerman, M. A.; Offerhaus, G. J. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology, 1996, 111 (1), 165-171.
87. Trauner, M.; Graziadei, I. W. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol. Ther., 1999, 13 (8), 979-996.
88. Combes, B. Ursodeoxycholic acid in primary biliary cirrhosis. Semin. Liver Dis., 1997, 17 (2), 125-128.
89. Wiesner, R. H. Current concepts in primary sclerosing cholangitis. Mayo. Clin. Proc., 1994, 69 (10), 969-982.
90. Neuman, M.; Cameron, R.; Shear, N.; Blendis, L. Electron microscopic study on antifibrotic effects of ursodeoxycholate treatment in primary biliary cirrhosis. In: Bile Acids and Cholestasis, Paumgartner, G.; Stiehl, A.; Gerok, W.; Keppler, D.; Leuschner, U., Eds.; Kluwer Academic Publishers: London, 1999; pp 254-269.
91. Lirussi, F.; Beccarello, A.; Bortolato, L.; Morselli-Labate, A. M.; Crovatto, M.; Ceselli, S.; Santini, G.; Crepaldi, G. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver, 1999, 19 (5), 381-388.
92. Neuman, M. G.; Shear, N. H.; Bellentani, S.; Tiribelli, C. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology, 1998, 115 (1), 157-166.
93. Joo, S. S.; Kang, H. C.; Won, T. J.; Lee, D. I. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia. Arch. Pharm. Res., 2003, 26 (12), 1067-1073.
94. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics 2002. CA Cancer J. Clin., 2005, 55 (2), 74-108.
95. Kelloff, G. J.; Lippman, S. M.; Dannenberg, A. J.; Sigman, C. C.; Pearce, H. L.; Reid, B. J.; Szabo, E.; Jordan, V. C.; Spitz, M. R.; Mills, G. B.; Papadimitrakopoulou, V. A.; Lotan, R.; Aggarwal, B. B.; Bresalier, R. S.; Kim, J.; Arun, B.; Lu, K. H.; Thomas, M. E.; Rhodes, H. E.; Brewer, M. A.; Follen, M.; Shin, D. M.; Parnes, H. L.; Siegfried, J. M.; Evans, A. A.; Blot, W. J.; Chow, W. H.; Blount, P. L.; Maley, C. C.; Wang, K. K.; Lam, S.; Lee, J. J.; Dubinett, S. M.; Engstrom, P. F.; Meyskens, F. L. Jr.; O'Shaughnessy, J.; Hawk, E. T.; Levin, B.; Nelson, W. G.; Hong, W. K. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin. Cancer Res., 2006, 12 (12), 3661-397.
96. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci., 1992, 17 (11), 463-468.
97. ACS, Cancer Facts and Figures, 2009. American Cancer Society Inc.: Atlanta, 2009; p. 72.
98. Kumagi, T.; Hiasa, Y.; Hirschfield, G. M. Hepatocellular carcinoma for the non-specialist. BMJ, 2009, 339, 1366-1370.
99. Calle, E. E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348 (17), 1625-1638.
100. Ratziu, V.; Bonyhay, L.; Di Martino, V.; Charlotte, F.; Cavallaro, L.; Sayegh-Tainturier, M. H.; Giral, P.; Grimaldi, A.; Opolon, P.; Poynard, T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology, 2002, 35(6), 1485-1493.
101. de Groen, P. C.; Gores, G. J.; LaRusso, N. F.; Gunderson, L. L.; Nagorney, D. M. Biliary tract cancers. N. Engl. J. Med., 1999, 341 (18), 1368-1378.
102. Khan, S. A.; Taylor-Robinson, S. D.; Toledano, M. B.; Beck, A.; Elliott, P.; Thomas, H. C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol., 2002, 37 (6), 806-813.
103. Shaib, Y. H.; El-Serag, H. B.; Davila, J. A.; Morgan, R.; McGlynn, K. A. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 2005, 128 (3), 620-626.
104. Hassid, V. J.; Orlando, F. A.; Awad, Z. T.; Tan, D.; Khoury, T.; Ahmed, B. H.; Alrawi, S. J. Genetic and molecular abnormalities in cholangiocarcinogenesis. Anticancer Res., 2009, 29 (4), 1151-1156.
105. Park, E. J.; Lee, J. H.; Yu, G. Y.; He, G.; Ali, S. R.; Holzer, R. G.; Osterreicher, C. H.; Takahashi, H.; Karin, M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010, 140 (2), 197-208.
106. Schwartz, J. J.; Hutson, W. R.; Gayowski, T. J.; Sorensen, J. B. Liver transplantation for cholangiocarcinoma. Transplantation, 2009, 88 (3), 295-298.
107. Matsumoto, Y.; Marusawa, H.; Kinoshita, K.; Endo, Y.; Kou, T.; Morisawa, T.; Azuma, T.; Okazaki, I. M.; Honjo, T.; Chiba, T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med., 2007, 13 (4), 470-476.
108. Takai, A.; Toyoshima, T.; Uemura, M.; Kitawaki, Y.; Marusawa, H.; Hiai, H.; Yamada, S.; Okazaki, I. M.; Honjo, T.; Chiba, T.; Kinoshita, K. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene, 2009, 28 (4), 469-478.
109. Karin, M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog., 2006, 45 (6), 355-361.
110. Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 2007, 7 (1), 41-51.
111. Murdoch, C.; Muthana, M.; Coffelt, S. B.; Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer, 2008, 8 (8), 618-631.
112. Zumsteg, A.; Christofori, G. Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr. Opin. Oncol., 2009, 21 (1), 60-70.
113. Pikarsky, E.; Porat, R. M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431 (7007), 461-466.
114. Aishima, S. I.; Taguchi, K. I.; Sugimachi, K.; Shimada, M.; Sugimachi, K.; Tsuneyoshi, M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology, 2002, 40 (3), 269-278.
115. Aggarwal, B. B. Nuclear factor-kappaB: the enemy within. Cancer Cell, 2004, 6 (3), 203-208.
116. Lee, J. S.; Heo, J.; Libbrecht, L.; Chu, I. S.; Kaposi-Novak, P.; Calvisi, D. F.; Mikaelyan, A.; Roberts, L. R.; Demetris, A. J.; Sun, Z.; Nevens, F.; Roskams, T.; Thorgeirsson, S. S. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med., 2006, 12 (4), 410-416.
117. Ellinger-Ziegelbauer, H.; Stuart, B.; Wahle, B.; Bomann, W.; Ahr, H. J. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat. Res., 2005, 575 (1-2), 61-84.
118. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J. M.; Gonzalez, F. J. Spontaneous hepatocarcinogenesis in farnesoid X receptornull mice. Carcinogenesis, 2007, 28 (5), 940-946.
119. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D. D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 2007, 67 (3), 863-867.
120. Narisawa, T.; Fukaura, Y.; Terada, K.; Sekiguchi, H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Cancer Sci., 1998, 89 (10), 1009-1013.
121. Ikegami, T.; Matsuzaki, Y.; Shoda, J.; Kano, M.; Hirabayashi, N.; Tanaka, N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett., 1998, 134 (2), 129-139.
122. Corpet, D. E.; Tache, S.; Peiffer, G. Colon tumor promotion: is it a selective process? Effects of cholate, phytate, and food restriction in rats on proliferation and apoptosis in normal and aberrant crypts. Cancer Lett., 1997, 114 (1-2), 135-138.
123. Earnest, D. L.; Holubec, H.; Wali, R. K.; Jolley, C. S.; Bissonette, M.; Bhattacharyya, A. K.; Roy, H.; Khare, S.; Brasitus, T. A. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res., 1994, 54 (19), 5071-5074.
124. Reddy, B. S.; Watanabe, K.; Weisburger, J. H.; Wynder, E. L. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res., 1977, 37 (9), 3238-3242.
125. van Nieuwkerk, C. M.; Groen, A. K.; Ottenhoff, R.; van Wijland, M.; van den Bergh Weerman, M. A.; Tytgat, G. N.; Offerhaus, J. J.; Oude Elferink, R. P. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J. Hepatol., 1997, 26 (1), 138-145.
126. Ismail, H.; Kalicinski, P.; Markiewicz, M.; Jankowska, I.; Pawlowska, J.; Kluge, P.; Eliadou, E.; Kaminski, A.; Szymczak, M.; Drewniak, T.; Revillon, Y. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transp., 1999, 3 (3), 219-224.
127. Jacquemin, E. Progressive familial intrahepatic cholestasis. Genetic basis and treatment. Clin. Liver Dis., 2000, 4 (4), 753-763.
128. Davit-Spraul, A.; Gonzales, E.; Baussan, C.; Jacquemin, E. Progressive familial intrahepatic cholestasis. Orphanet. J. Rare Dis., 2009, 4, 1.
129. Rosmorduc, O.; Hermelin, B.; Poupon, R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology, 2001, 120 (6), 1459-1467.